Immediate Impact

2 from Science/Nature 58 standout
Sub-graph 1 of 24

Citing Papers

Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Daijiro Harada being referenced

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
2017
JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation
2012

Author Peers

Author Last Decade Papers Cites
Daijiro Harada 682 812 353 72 1.2k
Akihiro Nishiyama 917 777 391 72 1.4k
Judit Moldvay 585 710 429 77 1.2k
Dale R. Shepard 458 463 402 71 1.1k
Takuro Kometani 589 616 551 43 1.2k
Kei Kunimasa 838 774 341 95 1.3k
Ken Suzawa 551 490 473 79 1.1k
Kosuke Tanaka 809 601 432 83 1.4k
Chung-Tsen Hsueh 296 539 406 53 1.1k
Vincenzo Sforza 351 662 369 58 1.1k
Michela Roberto 334 574 281 75 1.0k

All Works

Loading papers...

Rankless by CCL
2026